

**BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

<b>In the Matter of the Accusation</b>	)	
<b>Against:</b>	)	
	)	
	)	
<b>Thomas McNeese Keller, M.D.</b>	)	<b>Case No. 800-2017-030083</b>
	)	
<b>Physician's and Surgeon's</b>	)	
<b>Certificate No. G 27288</b>	)	
	)	
<b>Respondent</b>	)	
_____	)	

**DECISION**

**The attached Stipulated Surrender of License and Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.**

**This Decision shall become effective at 5:00 p.m. on November 25, 2019.**

**IT IS SO ORDERED November 18, 2019**

**MEDICAL BOARD OF CALIFORNIA**

By:   
Christine J. Lally  
Interim Executive Director

1 XAVIER BECERRA  
Attorney General of California  
2 JANE ZACK SIMON  
Supervising Deputy Attorney General  
3 LAWRENCE MERCER  
Deputy Attorney General  
4 State Bar No. 111898  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3488  
6 Facsimile: (415) 703-5480  
*Attorneys for Complainant*  
7

8 **BEFORE THE**  
9 **MEDICAL BOARD OF CALIFORNIA**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 800-2017-030083

13 **THOMAS MCNEESE KELLER, M.D.**

14 **751 Church Street**  
**Santa Rosa, CA 95405**

15 **Physician's and Surgeon's Certificate No. G**  
**27288**

**STIPULATED SURRENDER OF**  
**LICENSE AND ORDER**

16 Respondent.  
17

18 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
19 entitled proceedings that the following matters are true:

20 **PARTIES**

21 1. Kimberly Kirchmeyer (Complainant) is the Executive Director of the Medical Board  
22 of California (Board). She brought this action solely in her official capacity and is represented in  
23 this matter by Xavier Becerra, Attorney General of the State of California, by Lawrence Mercer,  
24 Deputy Attorney General.

25 2. Thomas McNeese Keller, M.D. (Respondent) is represented in this proceeding by his  
26 attorneys, Brock D. Phillips and Pacific West Law Group, LLP, 503 San Pedro Cove, San Rafael,  
27 CA 94901.  
28





1 ORDER

2 IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. G 27288, issued  
3 to Respondent Thomas McNeese Keller, M.D., is surrendered and accepted by the Board.

4 1. Respondent shall lose all rights and privileges as a physician and surgeon in  
5 California as of the effective date of the Board's Decision and Order.

6 2. Respondent shall cause to be delivered to the Board his pocket license and, if one was  
7 issued, his wall certificate on or before the effective date of the Decision and Order.

8 3. If Respondent ever files an application for licensure or a petition for reinstatement in  
9 the State of California, the Board shall treat it as a petition for reinstatement. Respondent must  
10 comply with all the laws, regulations and procedures for reinstatement of a revoked or  
11 surrendered license in effect at the time the petition is filed, and all of the charges and allegations  
12 contained in Accusation No. 800-2017-030083 shall be deemed to be true, correct and admitted  
13 by Respondent when the Board determines whether to grant or deny the petition.

14 4. If Respondent should ever apply or reapply for a new license or certification, or  
15 petition for reinstatement of a license, by any other health care licensing agency in the State of  
16 California, all of the charges and allegations contained in Accusation, No. 800-2017-030083 shall  
17 be deemed to be true, correct, and admitted by Respondent for the purpose of any Statement of  
18 Issues or any other proceeding seeking to deny or restrict licensure.

19 ACCEPTANCE

20 I have carefully read the above Stipulated Surrender of License and Order and have fully  
21 discussed it with my attorney. I understand the stipulation and the effect it will have on my  
22 Physician's and Surgeon's Certificate. I enter into this Stipulated Surrender of License and Order  
23 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the  
24 Medical Board of California.


25  
26 DATED: October 26, 2019

Thomas McNeese Keller, M.D.  
THOMAS MCNEESE KELLER, M.D.  
Respondent

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

I have read and fully discussed with Respondent Thomas McNeese Keller, M.D. the terms and conditions and other matters contained in this Stipulated Surrender of License and Order. I approve its form and content.

DATED: 11/3/2019


PACIFIC LAW GROUP, LLP  
  
BROCK D. PHILLIPS  
*Attorney for Respondent*

ENDORSEMENT

The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted for consideration by the Medical Board of California of the Department of Consumer Affairs.

DATED: 11/4/2019

Respectfully submitted,  
XAVIER BECERRA  
Attorney General of California  
JANE ZACK SIMON  
Supervising Deputy Attorney General

  
LAWRENCE MERCER  
Deputy Attorney General  
*Attorneys for Complainant*

SF2018201674  
21624551.docx

**Exhibit A**

**Accusation No. 800-2017-030083**

1 XAVIER BECERRA  
Attorney General of California  
2 JANE ZACK SIMON  
Supervising Deputy Attorney General  
3 LAWRENCE MERCER  
Deputy Attorney General  
4 State Bar No. 111898  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3488  
6 Facsimile: (415) 703-5480  
*Attorneys for Complainant*

FILED  
STATE OF CALIFORNIA  
MEDICAL BOARD OF CALIFORNIA  
SACRAMENTO *Dr. Keller* 3/20/18  
BY *[Signature]* ANALYST

8 BEFORE THE  
9 MEDICAL BOARD OF CALIFORNIA  
10 DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

11 In the Matter of the Accusation Against:

Case No. 800-2017-030083

12 **Thomas McNeese Keller, M.D.**  
13 **751 Church Street**  
**Santa Rosa, CA 95405**

**A C C U S A T I O N**

14 **Physician's and Surgeon's Certificate**  
15 **No. G 27288,**

16 Respondent.

17  
18 Complainant alleges:

19 **PARTIES**

20 1. Kimberly Kirchmeyer (Complainant) brings this Accusation solely in her official  
21 capacity as the Executive Director of the Medical Board of California, Department of Consumer  
22 Affairs (Board).

23 2. On or about July 19, 1974, the Medical Board issued Physician's and Surgeon's  
24 Certificate Number G 27288 to Thomas McNeese Keller, M.D. (Respondent). The Physician's  
25 and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought  
26 herein and will expire on February 28, 2019, unless renewed. Pursuant to a stipulated decision,  
27 Respondent's certificate was revoked, effective December 19, 1990, but was reinstated on August  
28 25, 1994, subject to the terms and conditions of a five-year probation. Said probation was



1 terminated by Order of the Board, effective June 13, 1997. Effective July 1, 2002, Respondent's  
2 certificate was subject to a public reprimand and, on February 19, 2003, a Public Letter of  
3 Reprimand issued.

4 **JURISDICTION**

5 3. This Accusation is brought before the Board, under the authority of the following  
6 laws. All section references are to the Business and Professions Code unless otherwise indicated.

7 4. Section 2227 of the Code states:

8 “(a) A licensee whose matter has been heard by an administrative law judge of the Medical  
9 Quality Hearing Panel as designated in Section 11371 of the Government Code, or whose default  
10 has been entered, and who is found guilty, or who has entered into a stipulation for disciplinary  
11 action with the board, may, in accordance with the provisions of this chapter:

12 “(1) Have his or her license revoked upon order of the board.

13 “(2) Have his or her right to practice suspended for a period not to exceed one year upon  
14 order of the board.

15 “(3) Be placed on probation and be required to pay the costs of probation monitoring upon  
16 order of the board.

17 “(4) Be publicly reprimanded by the board. The public reprimand may include a  
18 requirement that the licensee complete relevant educational courses approved by the board.

19 “(5) Have any other action taken in relation to discipline as part of an order of probation, as  
20 the board or an administrative law judge may deem proper.

21 “(b) Any matter heard pursuant to subdivision (a), except for warning letters, medical  
22 review or advisory conferences, professional competency examinations, continuing education  
23 activities, and cost reimbursement associated therewith that are agreed to with the board and  
24 successfully completed by the licensee, or other matters made confidential or privileged by  
25 existing law, is deemed public, and shall be made available to the public by the board pursuant to  
26 Section 803.1.”

27 //

28 //

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

5. Section 2234 of the Code, states:

“The board shall take action against any licensee who is charged with unprofessional conduct. In addition to other provisions of this article, unprofessional conduct includes, but is not limited to, the following:

“(a) Violating or attempting to violate, directly or indirectly, assisting in or abetting the violation of, or conspiring to violate any provision of this chapter.

“(b) Gross negligence.

“(c) Repeated negligent acts. To be repeated, there must be two or more negligent acts or omissions. An initial negligent act or omission followed by a separate and distinct departure from the applicable standard of care shall constitute repeated negligent acts.

“(1) An initial negligent diagnosis followed by an act or omission medically appropriate for that negligent diagnosis of the patient shall constitute a single negligent act.

“(2) When the standard of care requires a change in the diagnosis, act, or omission that constitutes the negligent act described in paragraph (1), including, but not limited to, a reevaluation of the diagnosis or a change in treatment, and the licensee’s conduct departs from the applicable standard of care, each departure constitutes a separate and distinct breach of the standard of care. . . .”

6. Section 725 of the Code states, in pertinent part:

“(a) Repeated acts of clearly excessive prescribing, furnishing, dispensing or administering drugs or treatment . . . as determined by the standard of the community of licensees is unprofessional conduct for a physician and surgeon . . . .”

7. Section 2266 of the Code states: “The failure of a physician and surgeon to maintain adequate and accurate records relating to the provision of services to their patients constitutes unprofessional conduct.”

//

//

1  
2 **FIRST CAUSE FOR DISCIPLINE**

3 **(Gross Negligence, Repeated Negligent Acts, Excessive Prescribing)**

4 8. Respondent is subject to disciplinary action under section 2234 and/or 2234(b) and/or  
5 2234(c) and/or 725 in that Respondent prescribed excessively and/or inappropriately to Patients 1  
6 through 5.<sup>1</sup> The circumstances are as follows:

7 Patient 1

8 9. On or about September 9, 2011, Patient 1, a 62 year old male, came under  
9 Respondent's care and treatment. Patient 1, a veteran being treated at the VA for a traumatic foot  
10 injury sustained in the Vietnam War, was referred to Respondent for treatment of chronic pain  
11 related to osteoarthritis of his shoulder and spine. Respondent prescribed methadone<sup>2</sup>, 5 mg, BID,  
12 Neurontin<sup>3</sup>, 200 mg, BID, Vicodin<sup>4</sup>, 10/500 mg PRN, and Ambien<sup>5</sup>, 10 mg, HS. The rationale for  
13 prescribing a sedating combination of drugs all at once and on the first patient encounter is not  
14 documented. Although the patient reported consuming four beers daily, an informed consent  
15 discussion advising the patient of the risks or recommending cessation, especially in light of the  
16 patient's neuropathy, is not documented beyond a general statement in the patient's medication  
17 agreement to make healthy lifestyle choices. Respondent did not order an EKG to evaluate for QT  
18 prolongation before starting the patient on methadone.

19 10. On September 22, 2011, the patient returned and reported that he was pleased with  
20 the relief provided by methadone. Respondent doubled the dosage of methadone at that time. At  
21 the next visit, on October 21, 2011, Respondent also increased the dosage of Neurontin and added  
22

23 <sup>1</sup> Patient's names are redacted to protect privacy.

24 <sup>2</sup> Methadone hydrochloride is a controlled substance and an opioid indicated for the  
25 treatment of pain severe enough to require around-the-clock long-term opioid management and  
26 for which alternative treatments have failed. Methadone exposes users to the risks of opioid  
27 addiction, misuse and abuse, which can lead to overdose and death.

28 <sup>3</sup> Neurontin (gabapentin) is an anticonvulsant that is used to treat nerve pain.

<sup>4</sup> Vicodin (hydrocodone bitartrate/acetaminophen) is a controlled substance used to  
control moderate to severe pain. Vicodin has a high potential for abuse.

<sup>5</sup> Ambien (zolpidem) is a controlled substance and a hypnotic used to treat insomnia.  
Ambien can cause dependence and, when taken in combination with opioids, can cause over-  
sedation and respiratory arrest.

1 a muscle relaxant, Soma<sup>6</sup>, but did not chart a rationale for the increases in the patient's  
2 medications.

3 11. On December 22, 2011, the patient reported that his pain medications had made him  
4 dizzy and that he had not taken any for two weeks; however, Respondent continued to prescribe.

5 12. On March 12, 2012, the patient reported having run out of methadone, at which time  
6 MS Contin<sup>7</sup>, 15 mg, QID, is substituted. Neither the reason for the change when the patient had  
7 only run out of his medication is explained, nor is Respondent's rationale for four daily doses of a  
8 12-hour pain medication documented. On September 3, 2012, the patient returned and asked to be  
9 placed back on the medications he had been taking in March, 2012. Respondent placed him on  
10 Opana<sup>8</sup>, 10 mg, BID. On September 24, 2012, the patient reported that Opana was not effective.  
11 Respondent increased the dosage to four times daily. The patient returned again on October 17<sup>th</sup>,  
12 2012, stating that the Opana made him lethargic-- at which time Respondent began him on  
13 Kadian<sup>9</sup>, an extended release pain reliever, 10 mg, BID. The dosage was increased to 20 mg, BID  
14 at the next visit and then increased again, to 30 mg, BID, a month later. On January 29, 2013,  
15 Respondent documented that he had increased the patient's dosage to Kadian, 20 mg, BID, and  
16 Kadian, 30 mg, BID. A rationale for these increases in medication is not documented by  
17 Respondent, other than to state the patient is "doing well" with Kadian.

18 13. In March, 2014, Respondent replaced the patient's Vicodin with Norco<sup>10</sup>, 5/325, QID,  
19 a short-acting narcotic, and increased the dosage to 10/325 mg, QID, in June 2014. In September  
20

21 <sup>6</sup> Soma (carisoprodol) is a controlled substance and a muscle relaxer with pain relieving  
22 properties. When taken in combination with opioids, Soma increases the effects of the opioid and  
23 for that reason it has a high potential for misuse and abuse.

24 <sup>7</sup> MS Contin (morphine sulfate) is a controlled substance and a potent opioid intended for  
25 the management of pain severe enough to require daily, around-the-clock, long-term opioid  
26 management and for which alternative treatment options are inadequate. Morphine sulfate tablets  
27 expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead  
28 to overdose and death.

<sup>8</sup> Opana (oxymorphone) is a controlled substance and an opioid agonist used for around-  
the-clock, long-term opioid management. Opana exposes patients and other users to the risks of  
opioid addiction, abuse, and misuse, which can lead to overdose and death

<sup>9</sup> Kadian (morphine sulfate) is a controlled substance which has an extended release and  
therefore is a greater risk for overdose and death due to the larger amount of morphine present.

<sup>10</sup> Norco is a trade name for hydrocodone bitartrate and acetaminophen, a controlled  
substance and an opiate medication with the potential for habituation and use.

1 2014, Respondent added another short-acting opioid, Percocet<sup>11</sup>, 10/325 mg, QID. Respondent  
2 did not chart an explanation for prescribing two short-acting opioid medications. In 2016, towards  
3 the end of the patient's treatment under his care, Respondent added oxycodone<sup>12</sup>, a long-acting  
4 opioid, so that the patient was prescribed a total of 360 tablets/month of short- and long-acting  
5 opioid medications, resulting in a very high morphine equivalency without a documented  
6 justification.

7 14. On August 31, 2016, Patient 1 was seen by a nurse practitioner at the VA, who  
8 expressed concern about the large quantity of rapid-acting narcotics that the patient was receiving  
9 each month from Respondent. The patient was weaned from his narcotic medications and he  
10 transferred his care for osteoarthritis back to the VA.

11 Patient 2

12 15. Patient 2, a 61 year old male, came under Respondent's care for pain management  
13 related to cervical spondylosis on December 13, 2016. The patient reported that he was not  
14 currently taking any narcotics, but was taking Cymbalta<sup>13</sup>, 60 mg, BID, and applying a 4%  
15 lidocaine gel. At the first and only patient encounter, Respondent prescribed Percocet, 10/325 mg,  
16 #90 (two tablets TID), Restoril<sup>14</sup>, 30 mg, #15, and Soma, 350 mg, #45. Respondent also provided  
17 the patient with prescriptions for an additional two-month supply of Percocet at a higher dosage  
18 (2 tablets QID). Respondent did not document a rationale for providing a large supply of opioid  
19 medications at the initial visit or for prescribing a dosage that exceeded a standard starting dose  
20 for an opioid naïve patient. Respondent did not document a discussion with the patient about the  
21 risks of combining opioids, benzodiazepines and muscle relaxants. After the initial visit,  
22 Respondent was contacted by staff at the VA where Patient 2 was receiving care. The staff  
23 advised that Patient 2 had an opioid abuse disorder for which he had completed an opioid taper

24 <sup>11</sup> Percocet is a trade name for oxycodone and acetaminophen, a narcotic analgesic with  
25 multiple actions similar to those of morphine with a high potential for dependence and abuse.

26 <sup>12</sup> Oxycodone is a narcotic analgesic with multiple actions similar to those of morphine.  
27 Oxycodone is a controlled substance and is available in combination with other drugs or alone. It  
28 can produce drug dependence and, therefore has the potential for being abused.

<sup>13</sup> Cymbalta (duloxetine hydrochloride) is approved for treatment of chronic  
musculoskeletal pain, which can be caused by conditions such as osteoarthritis or fibromyalgia.

<sup>14</sup> Restoril (temazepam) is a controlled substance and a benzodiazepine used for the short-  
term management of insomnia.

1 and nearly completed a benzodiazepine taper. On December 27, 2016, Respondent advised the  
2 patient that he would no longer prescribe for him. On December 28, 2016, and January 30, 2017,  
3 Patient 2 filled the additional prescriptions that Respondent had given to him at his office visit.

4 Patient 3

5 16. Beginning on October 11, 2013, Patient 3, a 32 year old female, came under  
6 Respondent's care and treatment for chronic flank pain secondary to chronic kidney stones, albeit  
7 the kidney stones were non-obstructing. At the time of her initial visit, the patient was taking  
8 Vicodin 5/500 mg, QID, and Tylenol, 500 mg, QID. Respondent prescribed methadone, 5 mg,  
9 BID, and Norco, 10/325 mg, QID, with the plan to eliminate Norco from the regimen if  
10 methadone was tolerated. Respondent did not order a baseline EKG before prescribing  
11 methadone.

12 17. Patient 3 returned on October 25, 2013, complaining of a migraine headache.  
13 Respondent did not perform a neurological work up, but prescribed Fiorinal<sup>15</sup>. The patient  
14 reported that methadone was sedating and, on subsequent visits stated that she was not taking  
15 methadone, but was taking Norco and Tylenol and applying a lidocaine gel. In June 2014, the  
16 patient was tried on Percocet, 10/325 mg, BID, but she complained that it was too strong and  
17 desired to go back to Norco. In August 2014, the patient tested positive for alcohol on urinalysis,  
18 but Respondent did not chart a discussion of the risks of alcohol consumption in combination  
19 with opioid medications. The patient reported taking a methadone tablet with good relief and this  
20 medication was resumed at a higher dose (10 mg) in October, 2014. Respondent noted that the  
21 patient was only taking methadone "prn" (as needed for pain), which is atypical prescribing of  
22 that long-acting opioid, especially since the patient was already taking short-acting medications  
23 for breakthrough pain. Respondent did not chart a rationale for this atypical prescribing.

24 18. In mid-2015, Respondent began increasing the dosage of the patient's Norco from  
25 QID to two tablets TID and then again, to two tablets QID. At about this time, the patient again  
26 tested positive for alcohol on urinalysis, but a discussion of the risk of possible interaction with  
27

28 <sup>15</sup> Fiorinal (butalbital/aspirin/caffeine) are medications sometimes used to treat tension-  
type headaches

1 her opioid medications is not documented in Respondent's chart. By the end of 2015, the patient  
2 was taking Norco, 10/325 mg, 2 tablets TID and Percocet, 10/325 mg, HS, and methadone, 10  
3 mg, BID.

4 19. In April, 2016, Patient 3 told Respondent that she would undergo a tubal ligation  
5 reversal in order to become pregnant. After that procedure was performed, Patient 3 stated that  
6 she planned to discontinue her pain medications during her pregnancy. However, on July 29,  
7 2016, when she confirmed that she was pregnant, she relayed advice from her obstetrician that  
8 she could take low doses of Norco and even Percocet. Respondent did not document a  
9 consultation with Patient 3's obstetrician to develop a plan for opioids during pregnancy or later,  
10 breastfeeding, nor did he clarify what was meant by "low doses." Respondent did not document a  
11 discussion with the patient of the risks to her and her child of taking the medications or  
12 withdrawing from them. In fact, Respondent continued to prescribe Norco, 10/325 mg, QID, and  
13 Percocet 10/325 mg; BID, to Patient 3 during her pregnancy. Although the patient had again  
14 tested positive for alcohol, there was no discussion or plan for cessation. Respondent also added  
15 Tylenol/Codeine #3<sup>16</sup>, BID, for those occasions when she ran out of her pain medications before  
16 it was time to refill her prescriptions, but did not chart a discussion why she was exceeding the  
17 prescribed dosage. As the patient's pregnancy progressed, Respondent twice increased her dosage  
18 of Norco at her request. After Patient 3 gave birth, Respondent continued to prescribe Norco and  
19 Percocet, but did not record a history regarding whether the patient was breastfeeding.

20 Patient 4

21 20. Patient 4, a 58 year old female, came under Respondent's care beginning on June 13,  
22 2018. Patient 4's chief complaints were osteoarthritis of the hands, knees, neck and back. Due to  
23 a phobia regarding taking oral medication, Patient 4 was receiving an oral solution of oxycodone,  
24 15 cc, every three hours. Patient 4 was clearly habituated and likely addicted to the oral  
25 oxycodone -- a fact that Respondent recognized early on -- but Respondent did not utilize the  
26 CURES reporting system to detect abuse until after he had already discharged the patient. Had he  
27 utilized CURES, he would have discovered that the patient was obtaining opioids from another

28 <sup>16</sup> Tylenol/Codeine combination used to treat mild to moderate pain.

1 physician during several months that she was under Respondent's care. Although Respondent  
2 counseled the patient to try an alternative opioid in the form of fentanyl<sup>17</sup> patches, he allowed her  
3 make the decision to remain on the high dose, oral opioid based, albeit these decisions were based  
4 on explanations (such as the need to care for a relative in Oregon) that did not make medical  
5 sense. He did not offer non-pharmacologic pain management techniques. Although he prescribed  
6 non-opioid medications at her first visit, including Voltaren and lidocaine patches, these were not  
7 pursued. After 14 months of the patient's resistance to Respondent's repeated recommendations  
8 for a change in her medications, Respondent terminated his care of her.

9 Patient 5

10 21. Patient 5, a 79 year old male, came under Respondent's care on October 18, 2016, for  
11 chronic back and neck pain. The patient had a history significant for prior surgeries on his back  
12 and neck, obesity, diabetes mellitus and compromised cardiac status. At the initial evaluation,  
13 Respondent stated that the patient was stable on Percocet, 10/325 mg, QID, and his plan was to  
14 maintain him on that dosage, with the addition of a 2% lidocaine gel.

15 22. Despite his plan to maintain the patient on Percocet, 10/325 mg, QID, at the next  
16 several visits Respondent significantly increased the patient's opioid medications, so that by  
17 February 28, 2017, the patient was taking Percocet, two tablets QID, and oxycodone IR, BID.  
18 The only documented rationale for the increased opioid medication was the patient's desire for  
19 increases in his medication. When the patient reported that his medications were causing nausea,  
20 Respondent added Zofran, 8 mg, BID, to counteract the nausea but did not alter his treatment  
21 plan. On July 12, 2017, the patient returned, again complaining of the nausea related to  
22 oxycodone, and stated that he wanted to be on Percocet only. Despite this request, Respondent  
23 renewed all of his medications, including the oxycodone IR, BID, in July and again in September,  
24 2017.

25  
26  
27 <sup>17</sup> Fentanyl is a potent synthetic opioid analgesic. It is a controlled substance with a high  
28 potential for habituation and abuse. The basis for Respondent's determination that this would be a  
safer alternative is not documented.



1           23. In November, 2017, Respondent raised for the first time the high doses of opioid  
2 medications that he was prescribing to Patient 5, which he for the first time advised the patient  
3 was in excess of CDC and Medical Board prescribing guidelines and stated that a taper would be  
4 necessary. The patient expressed willingness to reduce his medications; however, rather than  
5 taper the patient's medications, Respondent discontinued the oxycodone IR entirely. In  
6 December, 2017, the patient returned stating that his pain was not tolerable on the medications  
7 prescribed, at which time Respondent told the patient that his only option was to be referred to  
8 another physician for placement of an intrathecal pump. When the patient refused the referral,  
9 Respondent terminated the patient from his practice.

10           Patients 1 through 5

11           24. Respondent is guilty of unprofessional conduct and Respondent's certificate is subject  
12 to disciplinary action based on his gross negligence and/or repeated negligent acts and/or  
13 excessive prescribing as set forth above and including, but not limited to, the following:

- 14           A. Respondent failed to develop and/or document a treatment plan related to the patients'  
15           symptoms and functioning in that Respondent increased or changed medications when  
16           the patients were stable;
- 17           B. Respondent excessively prescribed opioids and other controlled substances;
- 18           C. Respondent prescribed inappropriate combinations of drugs, including combinations of  
19           short-acting opioids and combinations of opioids and benzodiazepines;
- 20           D. Respondent failed to order appropriate tests, including baseline EKGs for patient who  
21           were prescribed methadone;
- 22           E. Respondent failed to provide adequate informed consent regarding the risks posed by  
23           the quantities and combinations of opioids, benzodiazepines and other drugs he  
24           prescribed;
- 25           F. Respondent failed to obtain appropriate consultations, such as consultation with Patient  
26           3's treating obstetrician.

27 //

28

